Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Author information

1
Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: M.F.Herbert-Fransen@lumc.nl.
2
Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands.
3
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands.
4
Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands; ISA Pharmaceuticals, Leiden, The Netherlands.

Abstract

Slow-release delivery has great potential for specifically targeting immune-modulating agents into the tumor-draining area. In prior work we showed that local treatment of slowly delivered anti-CD40 antibody induced robust anti-tumor CD8+ T cell responses without systemic toxicity. We now report on the comparison of two slow-release delivery systems for their use in antibody-based immunotherapy of cancer. Anti-CD40 agonistic antibody delivered locally in mineral oil Montanide ISA 51 or in dextran-based microparticles activated tumor-specific T cell activation. Both slow-release formulations significantly decreased systemic side-effects compared to systemic administration of anti-CD40 antibody. However, dextran-based microparticles caused serious local inflammation associated with unwanted rapid outgrowth of tumors instead of the tumor clearance observed with delivery in Montanide. We therefore conclude that Montanide ISA 51 is to be preferred as a slow-release agent for CD40 agonist immunotherapy of cancer.

KEYWORDS:

Cancer immunotherapy; Microparticles; Monoclonal antibodies; Side-effects; Slow-release

PMID:
24508038
DOI:
10.1016/j.vaccine.2014.01.056
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center